Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc is advancing its clinical-stage programs aimed at revolutionizing the treatment landscape for hepatitis B virus (HBV) and dysbiotic microbiomes, primarily generating revenue from its HBV cure initiatives. The promising interim Phase 1b data for ABI-5366 indicates robust antiviral activity and supports progressing towards Phase 2, while Gilead's collaboration enhances financial stability and reduces risks associated with Assembly's pipeline. Additionally, the potential for innovative oral regimens to significantly expand the market for HSV treatment further solidifies Assembly’s position as a leading player in the development of next-generation antivirals.

Bears say

Assembly Biosciences Inc faces significant challenges that contribute to a negative outlook on its stock, largely stemming from clinical development risks associated with its drug candidates ABI-6250 and ABI-5366, where concerns over biomarker-driven progression and virologic endpoints persist. Additionally, reliance on Gilead as a primary strategic collaborator introduces opt-in risk, especially if Gilead delays or decides against proceeding with the programs, further complicating the company’s commercialization efforts. Assembly also confronts potential dilution risk if it seeks additional capital before achieving key opt-in or milestone events, alongside manufacturing and regulatory delays that could impede progress in its platform programs.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.